Chang-Ching Lin
University of Texas Southwestern Medical Center
H-index: 13
North America-United States
Top articles of Chang-Ching Lin
Abstract PS17-09: An FGFR1/2 degrader overcomes antiestrogen resistance in ER+/FGFR1-amplified breast cancer
Cancer Research
2024/5/2
Chang-Ching Lin
H-Index: 7
Dan Ye
H-Index: 6
Luigi Formisano
H-Index: 20
Saurabh Mendiratta
H-Index: 9
Ariella Hanker
H-Index: 13
Abstract PO1-23-09: A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+ …
Cancer Research
2024/5/2
Abstract PO3-23-09: ESR1 mutations drive resistance to CDK4/6 inhibitors in ER+ Breast Cancer
Cancer Research
2024/5/2
Abstract PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer
Cancer Research
2024/5/2
Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)
Cancer Research
2023/4/4
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Nature communications
2024/3/13
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Research Square
2023/7/10
PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer
Cancer Research
2023/4/4
Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy
Cancer Research
2023/4/4
Abstract P5-02-02: Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
Cancer Research
2023/3/1
Chang-Ching Lin
H-Index: 7
Ariella Hanker
H-Index: 13
Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer
Cancer immunology research
2022/7/1
Abstract GS3-09: Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer
Cancer Research
2022/2/15
Abstract P5-17-09: A genome-wide CRISPR screen identifies PRMT5 as a novel therapeutic target in ER+/RB1-deficient breast cancer
Cancer Research
2022/2/15
Chang-Ching Lin
H-Index: 7
Kyung-Min Lee
H-Index: 8
He Zhang
H-Index: 4
Yunguan Wang
H-Index: 6
Dan Ye
H-Index: 6
Yang Xie
H-Index: 18
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Cancer cell
2021/8/9
Benjamin P Brown
H-Index: 24
Dan Ye
H-Index: 6
Chang-Ching Lin
H-Index: 7
Kyung-Min Lee
H-Index: 8
Jie He
H-Index: 12
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer
Clinical Cancer Research
2021/8/1
Abstract GS1-06: FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer
Cancer Research
2021/2/15
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer
Nature communications
2020/10/30
Combined p53-and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer
Journal of Biological Chemistry
2020/8/21
Corrigendum to “Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer”[Canc. Lett. 438 (2018, Dec 1) 165–173](Cancer Letters (2018) 438 (165–173 …
Cancer Letters
2020/6/28
Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
Cancer Research
2020/2/15
